The Adenosine Hypothesis of Restless Legs Syndrome

Overview

Journal J Caffeine Adenosine Res

Date 2019 Apr 5

PMID 30944909

Citations 1

Authors

Sergi Ferre

Affiliations

Soon will be listed here.

Citing Articles

Cognitive profile in Restless Legs Syndrome: A signal-to-noise ratio account.

Colzato L, Zhang W, Brandt M, Stock A, Beste C Curr Res Neurobiol. 2022; 2:100021.

PMID: 36246509 PMC: 9559071. DOI: 10.1016/j.crneur.2021.100021.

References

Dooley D, Taylor C, Donevan S, Feltner D . Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007; 28(2):75-82. DOI: 10.1016/j.tips.2006.12.006. View

Rivera-Oliver M, Moreno E, Alvarez-Bagnarol Y, Ayala-Santiago C, Cruz-Reyes N, Molina-Castro G . Adenosine A-Dopamine D Receptor Heteromers Control the Excitability of the Spinal Motoneuron. Mol Neurobiol. 2018; 56(2):797-811. PMC: 6252157. DOI: 10.1007/s12035-018-1120-y. View

Lanza G, Cantone M, Lanuzza B, Pennisi M, Bella R, Pennisi G . Distinctive patterns of cortical excitability to transcranial magnetic stimulation in obstructive sleep apnea syndrome, restless legs syndrome, insomnia, and sleep deprivation. Sleep Med Rev. 2014; 19:39-50. DOI: 10.1016/j.smrv.2014.04.001. View

Allen R, Walters A, Montplaisir J, Hening W, Myers A, Bell T . Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005; 165(11):1286-92. DOI: 10.1001/archinte.165.11.1286. View

Ferre S, Garcia-Borreguero D, Allen R, Earley C . New Insights into the Neurobiology of Restless Legs Syndrome. Neuroscientist. 2018; 25(2):113-125. PMC: 9372713. DOI: 10.1177/1073858418791763. View

Ferre S, Quiroz C, Guitart X, Rea W, Seyedian A, Moreno E . Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome. Front Neurosci. 2018; 11:722. PMC: 5766678. DOI: 10.3389/fnins.2017.00722. View

Brown R, Basheer R, McKenna J, Strecker R, McCarley R . Control of sleep and wakefulness. Physiol Rev. 2012; 92(3):1087-187. PMC: 3621793. DOI: 10.1152/physrev.00032.2011. View

Yepes G, Guitart X, Rea W, Newman A, Allen R, Earley C . Targeting hypersensitive corticostriatal terminals in restless legs syndrome. Ann Neurol. 2017; 82(6):951-960. PMC: 5739944. DOI: 10.1002/ana.25104. View

Ferre S, Quiroz C, Rea W, Guitart X, Garcia-Borreguero D . Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transport. Adv Pharmacol. 2019; 84:3-19. PMC: 9372712. DOI: 10.1016/bs.apha.2018.12.005. View

10.

Garcia-Borreguero D, Patrick J, Dubrava S, Becker P, Lankford A, Chen C . Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep. 2014; 37(4):635-43. PMC: 4044751. DOI: 10.5665/sleep.3558. View

11.

Connor J, Wang X, Allen R, Beard J, Wiesinger J, Felt B . Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain. 2009; 132(Pt 9):2403-12. PMC: 2732265. DOI: 10.1093/brain/awp125. View

12.

Allen R, Stillman P, Myers A . Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics. Sleep Med. 2009; 11(1):31-7. DOI: 10.1016/j.sleep.2009.03.007. View

13.

Garcia-Borreguero D, Cano-Pumarega I . New concepts in the management of restless legs syndrome. BMJ. 2017; 356:j104. DOI: 10.1136/bmj.j104. View

14.

Garcia-Borreguero D, Guitart X, Garcia Malo C, Cano-Pumarega I, Granizo J, Ferre S . Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. Sleep Med. 2018; 45:94-97. DOI: 10.1016/j.sleep.2018.02.002. View

15.

Li X, Eisenach J . Adenosine reduces glutamate release in rat spinal synaptosomes. Anesthesiology. 2005; 103(5):1060-5. DOI: 10.1097/00000542-200511000-00021. View

16.

Earley C, Connor J, Garcia-Borreguero D, Jenner P, Winkelman J, Zee P . Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease). Sleep Med. 2014; 15(11):1288-301. DOI: 10.1016/j.sleep.2014.05.009. View

17.

Quiroz C, Gulyani S, Ruiqian W, Bonaventura J, Cutler R, Pearson V . Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome. Neuropharmacology. 2016; 111:160-168. PMC: 5056844. DOI: 10.1016/j.neuropharm.2016.09.002. View

18.

Trenkwalder C, Allen R, Hogl B, Clemens S, Patton S, Schormair B . Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurol. 2018; 17(11):994-1005. DOI: 10.1016/S1474-4422(18)30311-9. View

19.

Ferre S . Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine. J Alzheimers Dis. 2010; 20 Suppl 1:S35-49. PMC: 9361505. DOI: 10.3233/JAD-2010-1400. View

20.

Salminen A, Manconi M, Rimpila V, Luoto T, Koskinen E, Ferri R . Disconnection between periodic leg movements and cortical arousals in spinal cord injury. J Clin Sleep Med. 2013; 9(11):1207-9. PMC: 3805809. DOI: 10.5664/jcsm.3174. View